Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 5Unknown 3Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Dermatologic 1Breast 1

Conditions

Melanoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Myelomonocytic, Chronic 1Hemangiosarcoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Cisplatin 11Gemcitabine 10Radiotherapy, Intensity-Modulated 6Capecitabine 6Drug Therapy 3Docetaxel 3toripalimab 2spartalizumab 2pembrolizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1olaparib 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × spartalizumab × Clear all
NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
150 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Novartis

Phase 1 Active not recruiting
98 enrolled
BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡